Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Recruiting
Phase 1
Phase 2
Interventional Study
Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 60 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Fully understand this study and voluntarily sign the ICF；
* Age ≥18 at ICF signing, regardless of gender；
* Histologically confirmed relapsed or refractory lymphoma.
Exclusion Criteria:
* Lymphoma with known CNS involvement；
* Severe cardiovascular/cerebrovascular diseases.
…
Contacts